Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis

Detalhes bibliográficos
Autor(a) principal: Sampaio, Diana Brasil Pedral
Data de Publicação: 2004
Outros Autores: Alves, Carmosina R., Martins Netto, Eduardo, Brites, Carlos, Badaró, Roberto José da Silva, Oliveira, Adriano S.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/5029
Resumo: p. 211-216
id UFBA-2_c42bda1587f8460e5d8c5e2cadac8e45
oai_identifier_str oai:repositorio.ufba.br:ri/5029
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Sampaio, Diana Brasil PedralAlves, Carmosina R.Martins Netto, EduardoBrites, CarlosBadaró, Roberto José da SilvaOliveira, Adriano S.Sampaio, Diana Brasil PedralAlves, Carmosina R.Martins Netto, EduardoBrites, CarlosBadaró, Roberto José da SilvaOliveira, Adriano S.2012-01-04T12:58:59Z2012-01-04T12:58:59Z20041678-4391http://www.repositorio.ufba.br/ri/handle/ri/50298(3)p. 211-216Forty-nine AIDS patients, most of who were antiretroviral therapy (ARV) naïve, with active tuberculosis, were treated with Rifampin 600mg, Isoniazid 400mg and Pirazinamide 2g daily. They also received ARV, consisting of Efavirenz (600mg/day) plus 2 NRTIs. All patients were prospectively followed for at least 24 months. Baselines were: male/female ratio 2:1, mean age 34.7 ± 9.4 yrs; weight 51 ± 9.0 kg, viral load 5.6 ± 0.6 logs, CD4 cell count 101 ± 128 cells/ mm3. Follow up mean values of data logs of VL and CD4 + cell /mm3 counts were: VL 1.7 and CD4 + 265; VL 1.3 and CD4 + 251; VL 1.4 and CD4 + 326 at 6, 12 and 24 months, respectively. Weight gain changes were: 5 ± 9.9 ± 12 and 21 ± 16 kg respectively at 6, 12 and 24 months. A non-concomitant ARV regimen was introduced at least three weeks after TB treatment initiation. Severe adverse reactions included rash (two), toxic hepatitis (six), Immune Reconstitution Syndrome (seven), and four deaths. We conclude that Efavirenz at a daily dose of 600 mg is sufficient and safe to treat HIV/TB patients using a Rifampin containing regimen.Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2012-01-04T12:58:59Z No. of bitstreams: 1 21618.pdf: 82391 bytes, checksum: 08affc43251f661dc94a59044aca5018 (MD5)Made available in DSpace on 2012-01-04T12:58:59Z (GMT). No. of bitstreams: 1 21618.pdf: 82391 bytes, checksum: 08affc43251f661dc94a59044aca5018 (MD5) Previous issue date: 2008TuberculosisHIV/AIDSdrug interactionRifampinEfavirenzantiretroviral therapyEfficacy and Safety of Efavirenz in HIV Patients on Rifampin for TuberculosisThe Brazilian Journal of Infectious Diseasesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAinfo:eu-repo/semantics/openAccessORIGINAL21618.pdf21618.pdfapplication/pdf82391https://repositorio.ufba.br/bitstream/ri/5029/1/21618.pdf08affc43251f661dc94a59044aca5018MD51LICENSElicense.txtlicense.txttext/plain1762https://repositorio.ufba.br/bitstream/ri/5029/2/license.txt1b89a9a0548218172d7c829f87a0eab9MD52TEXT21618.pdf.txt21618.pdf.txtExtracted texttext/plain19589https://repositorio.ufba.br/bitstream/ri/5029/3/21618.pdf.txtf5c935347f2ea1e3a084cffba0ac3908MD53ri/50292022-07-05 14:03:52.474oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:52Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
dc.title.alternative.pt_BR.fl_str_mv The Brazilian Journal of Infectious Diseases
title Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
spellingShingle Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
Sampaio, Diana Brasil Pedral
Tuberculosis
HIV/AIDS
drug interaction
Rifampin
Efavirenz
antiretroviral therapy
title_short Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
title_full Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
title_fullStr Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
title_full_unstemmed Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
title_sort Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis
author Sampaio, Diana Brasil Pedral
author_facet Sampaio, Diana Brasil Pedral
Alves, Carmosina R.
Martins Netto, Eduardo
Brites, Carlos
Badaró, Roberto José da Silva
Oliveira, Adriano S.
author_role author
author2 Alves, Carmosina R.
Martins Netto, Eduardo
Brites, Carlos
Badaró, Roberto José da Silva
Oliveira, Adriano S.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Sampaio, Diana Brasil Pedral
Alves, Carmosina R.
Martins Netto, Eduardo
Brites, Carlos
Badaró, Roberto José da Silva
Oliveira, Adriano S.
Sampaio, Diana Brasil Pedral
Alves, Carmosina R.
Martins Netto, Eduardo
Brites, Carlos
Badaró, Roberto José da Silva
Oliveira, Adriano S.
dc.subject.por.fl_str_mv Tuberculosis
HIV/AIDS
drug interaction
Rifampin
Efavirenz
antiretroviral therapy
topic Tuberculosis
HIV/AIDS
drug interaction
Rifampin
Efavirenz
antiretroviral therapy
description p. 211-216
publishDate 2004
dc.date.issued.fl_str_mv 2004
dc.date.accessioned.fl_str_mv 2012-01-04T12:58:59Z
dc.date.available.fl_str_mv 2012-01-04T12:58:59Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/5029
dc.identifier.issn.none.fl_str_mv 1678-4391
dc.identifier.number.pt_BR.fl_str_mv 8(3)
identifier_str_mv 1678-4391
8(3)
url http://www.repositorio.ufba.br/ri/handle/ri/5029
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/5029/1/21618.pdf
https://repositorio.ufba.br/bitstream/ri/5029/2/license.txt
https://repositorio.ufba.br/bitstream/ri/5029/3/21618.pdf.txt
bitstream.checksum.fl_str_mv 08affc43251f661dc94a59044aca5018
1b89a9a0548218172d7c829f87a0eab9
f5c935347f2ea1e3a084cffba0ac3908
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459391527026688

Registros relacionados